458 related articles for article (PubMed ID: 30919786)
21. Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation.
Khan S; Baboota S; Ali J; Narang RS; Narang JK
Drug Dev Ind Pharm; 2016; 42(2):209-20. PubMed ID: 26016780
[TBL] [Abstract][Full Text] [Related]
22. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs.
Hu L; Tang X; Cui F
J Pharm Pharmacol; 2004 Dec; 56(12):1527-35. PubMed ID: 15563759
[TBL] [Abstract][Full Text] [Related]
23. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
Dudhipala N; Veerabrahma K
Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
[TBL] [Abstract][Full Text] [Related]
24. Preparation, characterization and pharmacokinetic studies of linalool-loaded nanostructured lipid carriers.
Shi F; Zhao Y; Firempong CK; Xu X
Pharm Biol; 2016 Oct; 54(10):2320-8. PubMed ID: 26986932
[TBL] [Abstract][Full Text] [Related]
25. Solid lipid nanoparticles for sustained pulmonary delivery of Yuxingcao essential oil: Preparation, characterization and in vivo evaluation.
Zhao Y; Chang YX; Hu X; Liu CY; Quan LH; Liao YH
Int J Pharm; 2017 Jan; 516(1-2):364-371. PubMed ID: 27884712
[TBL] [Abstract][Full Text] [Related]
26. Optimization of nimesulide-loaded solid lipid nanoparticles (SLN) by factorial design, release profile and cytotoxicity in human Colon adenocarcinoma cell line.
Campos JR; Fernandes AR; Sousa R; Fangueiro JF; Boonme P; Garcia ML; Silva AM; Naveros BC; Souto EB
Pharm Dev Technol; 2019 Jun; 24(5):616-622. PubMed ID: 30477410
[TBL] [Abstract][Full Text] [Related]
27. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting.
Aji Alex MR; Chacko AJ; Jose S; Souto EB
Eur J Pharm Sci; 2011 Jan; 42(1-2):11-8. PubMed ID: 20971188
[TBL] [Abstract][Full Text] [Related]
28. Development and Optimization of Mirabegron Solid Lipid Nanoparticles as an Oral Drug Delivery for Overactive Bladder.
Raut P; Gambhire M; Panchal D; Gambhire V
Pharm Nanotechnol; 2021; 9(2):120-129. PubMed ID: 33504321
[TBL] [Abstract][Full Text] [Related]
29. RGD modified and PEGylated lipid nanoparticles loaded with puerarin: Formulation, characterization and protective effects on acute myocardial ischemia model.
Dong Z; Guo J; Xing X; Zhang X; Du Y; Lu Q
Biomed Pharmacother; 2017 May; 89():297-304. PubMed ID: 28236703
[TBL] [Abstract][Full Text] [Related]
30. Optimization of linalool-loaded solid lipid nanoparticles using experimental factorial design and long-term stability studies with a new centrifugal sedimentation method.
Pereira I; Zielińska A; Ferreira NR; Silva AM; Souto EB
Int J Pharm; 2018 Oct; 549(1-2):261-270. PubMed ID: 30075252
[TBL] [Abstract][Full Text] [Related]
31. Lipid-based nano-formulation platform for eplerenone oral delivery as a potential treatment of chronic central serous chorioretinopathy:
Abd-Elhakeem E; El-Nabarawi M; Shamma R
Drug Deliv; 2021 Dec; 28(1):642-654. PubMed ID: 33787445
[TBL] [Abstract][Full Text] [Related]
32. Development of solid lipid nanoparticles as carriers for improving oral bioavailability of glibenclamide.
Gonçalves LM; Maestrelli F; Di Cesare Mannelli L; Ghelardini C; Almeida AJ; Mura P
Eur J Pharm Biopharm; 2016 May; 102():41-50. PubMed ID: 26925503
[TBL] [Abstract][Full Text] [Related]
33. Effects of Formulation Variables on the Particle Size and Drug Encapsulation of Imatinib-Loaded Solid Lipid Nanoparticles.
Gupta B; Poudel BK; Pathak S; Tak JW; Lee HH; Jeong JH; Choi HG; Yong CS; Kim JO
AAPS PharmSciTech; 2016 Jun; 17(3):652-62. PubMed ID: 26304931
[TBL] [Abstract][Full Text] [Related]
34. Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles.
Silva AC; Kumar A; Wild W; Ferreira D; Santos D; Forbes B
Int J Pharm; 2012 Oct; 436(1-2):798-805. PubMed ID: 22867992
[TBL] [Abstract][Full Text] [Related]
35. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles.
Suresh G; Manjunath K; Venkateswarlu V; Satyanarayana V
AAPS PharmSciTech; 2007 Mar; 8(1):24. PubMed ID: 17408223
[TBL] [Abstract][Full Text] [Related]
36. Lipid-Based Gliclazide Nanoparticles for Treatment of Diabetes: Formulation, Pharmacokinetics, Pharmacodynamics and Subacute Toxicity Study.
Nazief AM; Hassaan PS; Khalifa HM; Sokar MS; El-Kamel AH
Int J Nanomedicine; 2020; 15():1129-1148. PubMed ID: 32110012
[TBL] [Abstract][Full Text] [Related]
37. A study to enhance the oral bioavailability of s-adenosyl-l-methionine (SAMe): SLN and SLN nanocomposite particles.
Amasya G; Ergin AD; Erkan Cakirci O; Ozçelikay AT; Sezgin Bayindir Z; Yuksel N
Chem Phys Lipids; 2021 Jul; 237():105086. PubMed ID: 33930379
[TBL] [Abstract][Full Text] [Related]
38. Preparation and pharmacokinetic evaluation of Tashinone IIA solid lipid nanoparticles.
Liu J; Zhu J; Du Z; Qin B
Drug Dev Ind Pharm; 2005 Jul; 31(6):551-6. PubMed ID: 16109628
[TBL] [Abstract][Full Text] [Related]
39. Enhancement in antifungal activity of eugenol in immunosuppressed rats through lipid nanocarriers.
Garg A; Singh S
Colloids Surf B Biointerfaces; 2011 Oct; 87(2):280-8. PubMed ID: 21689909
[TBL] [Abstract][Full Text] [Related]
40. Enhanced oral bioavailability of insulin-loaded solid lipid nanoparticles: pharmacokinetic bioavailability of insulin-loaded solid lipid nanoparticles in diabetic rats.
Ansari MJ; Anwer MK; Jamil S; Al-Shdefat R; Ali BE; Ahmad MM; Ansari MN
Drug Deliv; 2016 Jul; 23(6):1972-9. PubMed ID: 26017100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
